Aim: To establish proposal ultrasound parotid imaging reporting and data system (PIRADS) for classification and prediction of malignancy of parotid lesions and to assess the inter-observer agreement of this system.
Subjects And Methods: Retrospective analysis of ultrasound and power Duplex images of 142 patients with parotid lesions by two reviewers. Parotid focal lesions were classified into nine patterns and then categorized into five groups: PIRADS 1, definitively benign; PIRADS 2, probably benign; PIRADS 3, indeterminate; PIRADS 4, probably malignant; and PIRADS 5, highly suggestive malignant.
The Results: There was excellent interobserver agreement of both reviewers for patterns and PIRADS (K=0.84, P=0.001) with 92% percent agreement. There was excellent agreement of PIRADS 1 (K=1.00, P=0.001), PIRADS 2 (K=0.97, P=0.001), PIRADS 3 (K=0.86, P=0.001) and PIRADS 5 (K=0.88, P=0.001) and good agreement of PIRADS 4 (K=0.67, P=0.001). The Odds ratio of PIRADS 3, 4 and 5 were 1.36 (95% CI=0.39-4.55), 7.11 (95% CI=3.02-11.15) and 8.27 (95% CI=3.49-10.27) respectively. The accuracy was 92% and 90%, sensitivity was 79% and 65%, specificity was 94% and 96% of PIRADS of both reviewers respectively.
Conclusion: The proposed PIRADS is a reliable non-invasive imaging modality that can be used for categorizing parotid lesions and prediction of malignancy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejrad.2015.09.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transition zone-based prostate-specific antigen density for differentiating clinically significant prostate cancer in PI-RADS score 3 lesions.
Sci Rep
January 2025
Department of Radiology, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People's Hospital, Yancheng, China.
We intended to investigate the potential of several transitional zone (TZ) volume-related variables for the detection of clinically significant prostate cancer (csPCa) among lesions scored as Prostate Imaging Reporting and Data System (PI-RADS) category 3. Between September 2018 and August 2023, patients who underwent mpMRI examination and scored as PI-RADS 3 were queried from our institution. The diagnostic performances of prostate-specific antigen density (PSAD), TZ-adjusted PSAD (TZPSAD), and TZ-ratio (TZ volume/whole gland prostate volume) were analyzed.
View Article and Find Full Text PDFRisk of clinically significant prostate cancer undercategorized by multiparametric magnetic resonance imaging.
Abdom Radiol (NY)
January 2025
Department of Diagnostic and Interventional Radiology, Shanghai Eighth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: To investigative potential clinicopathological characteristics and imaging-related risk factors of clinically significant prostate cancer (csPCa) undercategorized in patients with negative or equivocal MRI.
Methods: This retrospective study included 581 patients with pathologically confirmed csPCa (Gleason score ≥ 3 + 4), including 108 undercategorized csPCa and 473 detected csPCa. All patients underwent multiparametric MRI (mpMRI).
Usefulness of urinary biomarker-based risk score and multiparametric MRI for clinically significant prostate cancer detection in biopsy-naïve patients.
Abdom Radiol (NY)
January 2025
Departmet of Urology, Medical Academy, Lithuanian University of Health Sciences, Mickeviciaus str. 9, Kaunas, 44307, Lithuania.
Objectives: This study aimed to investigate the accuracy of multiparametric magnetic resonance imaging (mpMRI), genetic urinary test (GUT), and prostate cancer prevention trial risk calculator version 2.0 (PCPTRC2) for the clinically significant prostate cancer (csPCa) diagnostic in biopsy-naïve patients.
Materials And Methods: In a single center study between 2021 and 2024 participants underwent prostate mpMRI, GUT, and ultrasound (US) guided biopsy.
Meeting Cancer Detection Benchmarks in MRI/Ultrasound Fusion Biopsy for Prostate Cancer: Insights from a Retrospective Analysis of Experienced Urologists.
Cancers (Basel)
January 2025
Department of Urology, St. Elisabeth Hospital Straubing, 94315 Straubing, Germany.
Background: The relationship between case volume and clinical outcomes is well established for most urological procedures but remains underexplored in prostate ultrasound/MRI fusion biopsy (UMFB). UMFB aims to detect clinically significant prostate cancer (csPCa) by adhering to cancer detection benchmarks for PI-RADS lesions identified via multiparametric MRI (mpMRI). These benchmarks, defined by Ahmed et al.
View Article and Find Full Text PDFDiscordance between prostate MRI and PSMA-PET/CT: the next big challenge for primary prostate tumor assessment?
Eur Radiol
January 2025
Department of Radiology, Oncologic Imaging Division, NYU Langone Health, New York, NY, USA.
Objectives: An increasing number of patients with prostate cancer (PCa) undergo assessment with magnetic resonance imaging (MRI) and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT). This offers comprehensive multimodality staging but can lead to discrepancies. The objective was to assess the rates and types of discordance between MRI and PSMA-PET/CT for primary PCa assessment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!